Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valion BioVBIO -8.74%23 PB Ratio is 0.11 as of Jul. 15, 2026, which is 84% below its 10-year median of 0.69. GuruFocus rates VBIO with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Valion Bio ranks better than 99.43% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Valion Bio's share price is $0.4282. Valion Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $3.84. Hence, Valion Bio's PB Ratio of today is 0.11.
Good Sign:
Valion Bio Inc stock PB Ratio (=0.12) is close to 5-year low of 0.11.
The historical rank and industry rank for Valion Bio's PB Ratio or its related term are showing as below:
VBIO'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.69 Max: 3.28
Current: 0.11
During the past 7 years, Valion Bio's highest PB Ratio was 3.28. The lowest was 0.11. And the median was 0.69.
VBIO's PB Ratio is ranked better than 99.43% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs VBIO: 0.11
During the past 12 months, Valion Bio's average Book Value Per Share Growth Rate was -10.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -77.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Valion Bio was 8.50% per year. The lowest was -87.30% per year. And the median was -77.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Valion Bio PB Ratio Related Terms
Valion Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Valion Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valion Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valion Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valion Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Valion Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Valion Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Valion Bio (VBIO) has a PB Ratio of 0.11 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valion Bio and its competitors. This is 84% below median its historical median of 0.69. Over the past decade, Valion Bio's PB Ratio has ranged from 0.11 to 3.28. According to the industry distribution chart, Valion Bio ranks #7 out of 1228 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Valion Bio's PB Ratio too high?
Valion Bio's current PB Ratio of 0.11 is 84% below median its 10-year median of 0.69. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 3.28. The Biotechnology industry median PB Ratio is 2.90. Valion Bio's value of 0.11 is 96.2% below this industry median. Based on the distribution chart, Valion Bio ranks #7 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valion Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's PB Ratio compare to BPTH and HEPA?
According to the Biotechnology industry distribution chart, Valion Bio ranks #7 out of 1228 companies for PB Ratio. This places Valion Bio in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. Valion Bio's value of 0.11 is 96.2% below this benchmark. Historically, Valion Bio's own PB Ratio has ranged from 0.11 to 3.28 over the past decade. While the company's 10-year median is 0.69 vs. the industry median of 2.90, Valion Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valion Bio's current PB Ratio of 0.11 is 96.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Valion Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valion Bio's current PB Ratio is 0.11, which is 84% below median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current PB Ratio of 0.11. The current PB Ratio is 0.11, which is 84% below median its 10-year median of 0.69 and 96.2% below the Biotechnology industry median of 2.90. Valion Bio's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Valion Bio (VBIO), the current PB Ratio is 0.11 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
23GF Score
Get the complete analysis for VBIO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VBIO has been successfully added to your 
